التفاصيل البيبلوغرافية
| العنوان: |
Current Treatment Options for the Management of Glioblastoma Multiforme. |
| المؤلفون: |
Buie, Larry W.1,2, Valgus, John M.1,3 |
| المصدر: |
Journal of Hematology Oncology Pharmacy. Jun2012, Vol. 2 Issue 2, p57-63. 7p. |
| مصطلحات موضوعية: |
*GLIOBLASTOMA multiforme treatment, *BEVACIZUMAB, *DRUG therapy, *RADIOTHERAPY, *CARCINOGENESIS, *ONCOLOGY |
| مستخلص: |
Background: Glioblastoma multiforme (GBM) is a highly malignant glial tumor characterized by rapid growth and angiogenesis. Current frontline therapy consists of surgical resection, radiation, and chemotherapy; however, all patients will progress. Over the past decade, there have been increases in the quality and quantity of clinical data regarding the treatment of patients with GBM. Objective: The purpose of this review is to describe the pathways of tumorigenesis, review relevant data in both the frontline and recurrent disease settings, and discuss the place in therapy of novel treatment options for GBM. Methods: Stupp and colleagues revolutionized the management of patients with GBM with their 2005 landmark study that demonstrated the benefits of surgery and radiotherapy plus concomitant and adjuvant temozolomide. Other studies have shown that after disease progression, the administration of bevacizumab alone and in combination with cytotoxic chemotherapy resulted in increased progression-free survival. Data also support the use of daily temozolomide in recurrent disease, leading to similar results, although there are no comparative studies with bevacizumab and temozolomide. Conclusion: Much progress has been made in the treatment of GBM. Despite these advances, nearly all patients progress after frontline therapy and options remain limited. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
